Roots Analysis

Biosimilars Market Outlook: USD 130.1 Billion by 2035 at a 16.7% CAGR

The global biosimilars market, valued at USD 28.0 billion in 2025, is projected to reach USD 32.3 billion in 2026 and USD 130.1 billion by 2035, representing a CAGR of 16.7% during the forecast period 2026 to 2035.

Global Biosimilars Market Share by Type of Manufacturers, till 2035

See What's in the Full Report – Request Your Complimentary Insights!

Market Report: Key Takeaways

Market Size & Trends

Monoclonal antibodies currently hold the highest share of the biosimilars market.
The oncological disorders segment dominates (~40%) the current market.
Based on the type of manufacturer, in-house developers capture the largest share of the market.
The hospital pharmacies segment is currently dominating (nearly 45%) the biosimilars market.
Europe currently holds the highest market share (over 50%).

Key Market Statistics

Market Size in 2026: $32.3 Billion
Estimated Market Size in 2035: $130.1 Billion
CAGR (2026-2035): 16.7%
Europe: Largest market in 2026
North America: Fastest growing region

What is Driving the Biosimilars Market Growth Through 2035?

Biosimilars market growth over the next decade is expected to be driven primarily by the increasing number of biologics approaching patent expiry, leading to the development of biosimilars that are clinically similar to their reference biologics. A reference biologic, also referred to as an originator biologic, is the originally approved biologic against which a biosimilar is compared. Biosimilar development relies on comparative analytical, pharmacokinetic and, where appropriate, pharmacodynamic biomarker evidence to demonstrate high similarity and no clinically meaningful differences in safety, purity and potency.

In recent years, the biologics industry has witnessed robust expansion, driven by the effectiveness of biologic therapies across chronic and complex disorders. However, the high cost of biologics places a significant economic burden on patients, payers and healthcare systems. As demand for biologics continues to rise, biosimilar developers are pursuing more affordable alternatives while maintaining comparable quality, safety and efficacy. Patent cliffs affecting established reference products, including biologics associated with Enbrel® (etanercept), Neupogen® (filgrastim) and Avastin® (bevacizumab) continue to broaden the addressable opportunity for biosimilar competition.

Recent activity in the broader follow-on peptide market includes generic liraglutide products and the development of semaglutide follow-on candidates. These products should be analyzed separately from biosimilars unless they are submitted through an applicable biosimilar regulatory pathway. Over the past few years, the domain has also witnessed increased investment and collaborative activity among biosimilar developers. Regulatory advancements and streamlined approval procedures have supported the development and commercialization of oncology biosimilars.

Manufacturing complexity remains an important barrier in the biosimilars market. Biosimilars are generally produced through recombinant production systems using living cells, and variations in cell lines, upstream and downstream processing, purification or scale-up can influence critical quality attributes. As a result, developers increasingly focus on manufacturing quality, process efficiency, regulatory compliance and reproducibility when transferring or scaling biosimilar processes.

Pharmacovigilance and post-market surveillance are also important after biosimilar launch. Regulators, manufacturers and healthcare providers continue to monitor real-world safety, immunogenicity and product performance to confirm that the biosimilar's benefit-risk profile remains consistent with the evidence generated during development and approval.

As demand for more affordable biologic alternatives grows, both in-house biosimilar development and outsourced development and manufacturing activity are expected to increase. This trend is poised to present attractive growth opportunities for biosimilar developers.

How is the Biosimilars Market Segmented?

Based on the research, the biosimilars market report is segmented by drug class, therapeutic area, type of manufacturer, distribution channel, geographical regions, and leading players. This segmentation enables investors, business development teams, hospital decision-makers and healthcare providers, R&D teams, and procurement teams, to assess the market opportunity most relevant to their strategic and operational priorities.

By Drug Class: Monoclonal Antibodies, Proteins, Peptides, and Others
By Therapeutic Area: Oncological Disorders, Autoimmune and Inflammatory Disorders, Hematological Disorders, Metabolic Disorders, and Other Disorders
By Type of Manufacturer: Contract Manufacturers and In-house Developers
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
By Geographical Regions: North America (US, Canada, and Mexico), Europe (France, Germany, Italy, Spain, UK, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, New Zealand, and Rest of the Asia-Pacific), Middle East & Africa (Egypt, Iran, Iraq, Israel, Saudi Arabia, South Africa, and United Arab Emirates), and Latin America (Argentina and Brazil)

Your Business is Unique – Why Shouldn't Your Report Be?

Biosimilars Pipeline and Developer Landscape: Key Insights

Biosimilars Pipeline Overview: Over 440 Biosimilars are Approved across the Globe

The market landscape features the presence of more than 900 biosimilars targeting a wide range of chronic disorders; of these, more than 170 biosimilars are currently being evaluated in different phases of clinical trials. Further, over 245 biosimilars are currently in the preclinical and discovery stage of development, indicating rising need for these therapies and substantial research and development activity.

Global Biosimilar Developers Landscape: Asia-Pacific Emerges as a Key Hub

The market landscape features the presence of more than 170 players, with different company sizes including, very large, large, mid-sized, small and very small. Close to 35% of these biosimilar developers were established pre-1990, demonstrating the presence of well-established stakeholders in the biosimilar's domain. Over 60% of the biosimilar companies are based in Asia-Pacific, followed by Europe, North America and the rest of the world. Within Asia-Pacific, India and China have emerged as major hubs for biosimilar development.

Key Market Drivers: Impending Patent Expiry of Blockbuster Biologics and Uptake of Biosimilars to Drive Market Growth

The biosimilars market size is estimated to be worth USD 32.3 billion in 2026. The market is expected to grow at a CAGR of 16.7% from 2026 to 2035, driven by the patent expiry of blockbuster biologics and increasing demand for biosimilars as a cost-effective alternative. It is worth noting that several biologics are anticipated to fall off the patent cliff in the near future. Positive biosimilar market trends have been noticed lately, reflected by sales data published by the biosimilar developers. For instance, in the first half of 2025, Sandoz biosimilars achieved sales of USD 1,496 million, a 12% increase in constant currency, driven by robust growth in Europe and international markets.

Recent Developments in the Biosimilars Industry

In February 2026, the US FDA accepted Dr. Reddy's 351(k) Biologics License Application for DRL_AB, a proposed interchangeable intravenous biosimilar to ORENCIA® (abatacept), for review.
In January 2026, Samsung Epis Holdings announced that Samsung Bioepis was adding six biosimilar candidates to its development pipeline, covering immunology, oncology and other therapeutic areas.
In October 2025, Hikma and Celltrion partnered to broaden access to six biosimilar treatments across the Middle East and North Africa (MENA) region. Under this partnership, Hikma holds exclusive commercialization rights in MENA while Celltrion handles development, manufacturing, and supply of biosimilars.
In June 2025, Alvotech and Dr. Reddy's entered into a collaboration and licensing agreement to co-develop, manufacture and commercialize AVT32, a proposed biosimilar to KEYTRUDA® (pembrolizumab), for global markets.
In March 2025, the US FDA approved Fresenius Kabi's denosumab biosimilars CONEXXENCE® and BOMYNTRA® for all indications of their respective reference products, Prolia® and Xgeva®.

Scope, Methodology and Industry Expert Interviews

The findings in this report were developed through a structured methodology combining secondary research, proprietary databases and primary interviews. Secondary research included company disclosures, regulatory databases, clinical-trial registries, peer-reviewed publications, patent records, pricing and reimbursement sources, and relevant market-access information. The biosimilars market is expected to continue expanding through 2035, supported by upcoming biologic patent expiries, regulatory streamlining and increasing adoption across major healthcare markets.

Commenting on the evolving biosimilars landscape, Dr. Stefan Glombitza, Chief Executive Officer of Formycon, stated, "In the evolving landscape of biologics, biosimilars have emerged from a regulatory concept to a critical solution addressing both patient access and healthcare sustainability. With the growing pressures on global healthcare systems and the imminent patent expiries of many biologics, the opportunity to provide effective, affordable treatment options has never been clearer. At Formycon, we are not just developing biosimilars, we are committed to leading this transformation, partnering with regulators and stakeholders to ensure these therapies reach patients worldwide and improve lives."

The biosimilars market report includes transcripts of the following other third-party discussions:

Senior VP and Head of Therapeutic Area Biosimilars, Large Company in the UK
Professor, University, Netherlands
Vice Chancellor, University, India

Kindly note that Roots Analysis is an independent market research and consulting firm. The report is not affiliated with, endorsed by or sponsored by any company, regulator or individual named or quoted in this report; company names and expert perspectives are included solely for factual and analytical context.

Pay Only for What You Need – The Best Way to Optimize

Which Drug Class Accounts for the Largest Share of the Biosimilars Industry?

The monoclonal antibodies segment currently captures the majority of the market share and is expected to remain dominant during the forecast period. The peptides therapeutics segment is expected to register the highest growth rate during the forecast period. There are over 70 peptide-based therapies available worldwide, and an increase in prescription-based peptide drugs is anticipated as many biologics approach potential patent expiry, leading to a rise in generic versions.

Will In-house Developers Continue to Hold the Largest Market Share?

The in-house developers currently capture the majority of the biosimilars market. The biosimilar contract-development and manufacturing services market is estimated to grow at a CAGR of 18.1% from 2026 to 2035.

Regional Analysis: Which Regions are Showing the Fastest Growth in Biosimilars Industry?

Europe: Dominating the Market by Securing Highest Share

Europe accounts for more than 50% of the biosimilars market, supported by demand for biologic treatments for chronic conditions, established biosimilar policies and increasing adoption among healthcare providers and patients. This growth is fueled by proactive government policies promoting biosimilar adoption, stringent regulatory guidelines from the European Medicines Agency (EMA), and increasing investments in research and development.

Global Biosimilars Market Size by Geographical Regions, 2026

Countries such as France, Germany, Italy, Spain, and the UK are leading contributors, benefiting from heightened disease burden and patent expiries of major biologics. At its September 2025 meeting, EMA's Committee for Medicinal Products for Human Use adopted positive opinions for nine biosimilar medicines, including seven denosumab products, one golimumab product and one ustekinumab product.

US Biosimilars Market

In the US, the rapid expansion of biosimilars market size is driven by several key factors, including a supportive regulatory environment established by the USFDA, which has streamlined the approval process for biosimilars and enhanced market access. Development, commercialization and partnership activity involving companies such as Amgen, Biocon, Viatris and Samsung Bioepis is supporting biosimilar competition and adoption in the US. Government policies, including the Inflation Reduction Act (IRA), promote biosimilar use, especially in Medicare. Payer demand and pharmacy benefit manager (PBM) incentives further support market growth.

The shifting distribution of biosimilars from hospitals to retail and specialty pharmacies is also fostering greater patient accessibility. In the US, biosimilar interchangeability refers to an additional regulatory designation that can permit pharmacy-level substitution for the reference product, subject to applicable state laws and dispensing requirements. Interchangeable biosimilars referencing products such as Humira and Stelara are expected to support broader adoption. For products suitable for subcutaneous administration, specialty and retail pharmacy channels can also influence site-of-care patterns and patient convenience. This growth is underpinned by ongoing innovation related to biosimilar technology, increased physician and patient acceptance, and strategic partnerships among stakeholders facilitating broader biosimilar adoption across the US healthcare system.

Get an Instant Quote in 10 Minutes. Lowest Price Guaranteed

Key Companies Engaged in Biosimilars Market

Examples of key biosimilar developers that have been profiled in the full report, arranged in alphabetical order, include Amgen, BIOCAD, Biocon, Celltrion, Coherus BioSciences, Dr. Reddy's Laboratories, Eli Lilly, Fresenius Kabi, Intas Pharmaceuticals, Pfizer, Sandoz, STADA, Teva Pharmaceutical. This market report includes an easily searchable excel database including all the drug developers that are engaged in the development of biosimilars.

Report Deliverables and Customization

Alongside the core market report, clients receive complimentary Excel data packs covering market landscape analysis, company competitiveness analysis, demand analysis, and market sizing and opportunity analysis. A complimentary PowerPoint presentation summarizing the full report is also included, and 15% free customization scope is available on request.

Report Authorship

This report was authored by Simriti Gupta, a member of the Roots Analysis healthcare and pharmaceutical research practice. Her work focuses on drug discovery and development, therapeutic-market assessment, competitive intelligence, clinical-pipeline analysis and market forecasting.

Independence and Non-Affiliation

This report is an independent work of market research and analysis published by Roots Analysis. It is not affiliated with, sponsored by, endorsed by, or reviewed by Amgen, BIOCAD, Biocon, Celltrion, Coherus BioSciences, Dr. Reddy's Laboratories, Eli Lilly, Fresenius Kabi, or any other pharmaceutical company, drug brand, or regulatory body referenced within it. No content in this report should be construed as medical advice. Roots Analysis maintains its own proprietary primary research process and does not receive compensation from any company profiled within the report, in exchange for inclusion or favorable characterization.

+ 1. PREFACE

1.1. Introduction

1.2. Market Share Insights

1.3. Key Market Insights

1.4. Report Coverage

1.5. Key Questions Answered

1.6. Chapter Outlines

+ 2. RESEARCH METHODOLOGY

2.1. Chapter Overview

2.2. Research Assumptions

2.2.1. Market Landscape and Market Trends

2.2.2. Market Forecast and Opportunity Analysis

2.2.3. Comparative Analysis

2.3. Database Building

2.3.1. Data Collection

2.3.2. Data Validation

2.3.3. Data Analysis

2.4. Project Methodology

2.4.1. Secondary Research

2.4.1.1. Annual Reports

2.4.1.2. Academic Research Papers

2.4.1.3. Company Websites

2.4.1.4. Investor Presentations

2.4.1.5. Regulatory Filings

2.4.1.6. White Papers

2.4.1.7. Industry Publications

2.4.1.8. Conferences and Seminars

2.4.1.9. Government Portals

2.4.1.10. Media and Press Releases

2.4.1.11. Newsletters

2.4.1.12. Industry Databases

2.4.1.13. Roots Proprietary Databases

2.4.1.14. Paid Databases and Sources

2.4.1.15. Social Media Portals

2.4.1.16. Other Secondary Sources

2.4.2. Primary Research

2.4.2.1. Types of Primary Research

2.4.2.1.1. Qualitative Research

2.4.2.1.2. Quantitative Research

2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research

2.4.2.3. Techniques for Primary Research

2.4.2.3.1. Interviews

2.4.2.3.2. Surveys

2.4.2.3.3. Focus Groups

2.4.2.3.4. Observational Research

2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research

2.4.2.4.1. Company Executives (CXOs)

2.4.2.4.2. Board of Directors

2.4.2.4.3. Company Presidents and Vice Presidents

2.4.2.4.4. Research and Development Heads

2.4.2.4.5. Technical Experts

2.4.2.4.6. Subject Matter Experts

2.4.2.4.7. Scientists

2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity

2.4.2.5.1. Research Ethics

2.4.2.5.2. Data Integrity

2.4.3. Analytical Tools and Databases

2.5. Robust Quality Control

+ 3. MARKET DYNAMICS

3.1. Chapter Overview

3.2. Forecast Methodology

3.2.1. Top-down Approach

3.2.2. Bottom-up Approach

3.2.3. Hybrid Approach

3.3. Market Assessment Framework

3.3.1. Total Addressable Market (TAM)

3.3.2. Serviceable Addressable Market (SAM)

3.3.3. Serviceable Obtainable Market (SOM)

3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques

3.4.1. Qualitative Forecasting

3.4.2. Correlation

3.4.3. Regression

3.4.4. Extrapolation

3.4.5. Convergence

3.4.6. Sensitivity Analysis

3.4.7. Scenario Planning

3.4.8. Data Visualization

3.4.9. Time Series Analysis

3.4.10. Forecast Error Analysis

3.5. Key Considerations

3.5.1. Demographics

3.5.2. Government Regulations

3.5.3. Reimbursement Scenarios

3.5.4. Market Access

3.5.5. Supply Chain

3.5.6. Industry Consolidation

3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

+ 4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview

4.2. Market Dynamics

4.2.1. Time Period

4.2.1.1. Historical Trends

4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage

4.2.2.1. Major Currencies Affecting the Market

4.2.2.2. Factors Affecting Currency Fluctuations

4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate

4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market

4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession

4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation

4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates

4.2.6.1. Interest Rates and Their Impact on the Market

4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis

4.2.7.1. Type of Commodity

4.2.7.2. Origins and Destinations

4.2.7.3. Values and Weights

4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics

4.2.8.1. Import Scenario

4.2.8.2. Export Scenario

4.2.8.3. Trade Policies

4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers

4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis

4.2.9.1. Russian-Ukraine War

4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors

4.2.10.1. Global Economic Impact

4.2.10.2. Industry-specific Impact

4.2.10.3. Government Response and Stimulus Measures

4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators

4.2.11.1. Fiscal Policy

4.2.11.2. Consumer Spending

4.2.11.3. Gross Domestic Product

4.2.11.4. Employment

4.2.11.5. Taxes

4.2.11.6. Stock Market Performance

4.2.11.7. Cross Border Dynamics

4.3. Conclusion

+ 5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape

5.2. Executive Summary: Market Trends

5.3. Executive Summary: Market Forecast and Opportunity Analysis

+ 6. INTRODUCTION

6.1. Chapter Overview

6.2. Overview of Biologics

6.3. Overview of Biosimilars and Biobetters

6.4. Difference between Innovator Biologics, Biosimilars and Generics

6.5. Advantages of Biosimilars

6.6. Manufacturing of Biosimilars

6.7. Development Timeline of Biosimilars

6.8. Future Perspectives

+ 7. MARKET LANDSCAPE

7.1. Chapter Overview

7.2. Biosimilars: Developers Landscape

7.2.1. Analysis by Year of Establishment

7.2.2. Analysis by Company Size

7.2.3. Analysis by Location of Headquarters (Region)

7.2.4. Analysis by Location of Headquarters (Country)

7.3. Biosimilars: Overall Market Landscape

7.3.1. Analysis by Stage of Development

7.3.2. Analysis by Therapeutic Area

7.3.3. Analysis by Drug Class

+ 8. COMPANY COMPETITIVENESS ANALYSIS

8.1. Chapter Overview

8.2. Methodology and Key Parameters

8.3. Scoring Criteria

8.4. Overview of Peer Groups

8.5. Biosimilar Developers: Company Competitiveness Analysis

8.5.1. Biosimilar Developers based in North America (Peer Group I)

8.5.2. Biosimilar Developers based in Europe (Peer Group II)

8.5.3. Biosimilar Developers in Asia-Pacific and Rest of the World (Peer Group III)

+ 9. COMPANY PROFILES: BIOSIMILAR DEVELOPERS IN NORTH AMERICA

9.1. Chapter Overview

9.2. Amgen

9.2.1. Company Overview

9.2.2. Financial Information

9.2.3. Biosimilar Pipeline

9.2.4. Recent Developments and Future Outlook

9.3. Coherus BioSciences

9.4. Eli Lilly

9.5. Pfizer

+ 10. COMPANY PROFILES: BIOSIMILAR DEVELOPERS BASED IN EUROPE

10.1. Chapter Overview

10.2. BIOCAD

10.2.1. Company Overview

10.2.2. Biosimilar Pipeline

10.2.3. Recent Developments and Future Outlook

10.3. Fresenius Kabi

10.4. Sandoz

10.5. STADA

+ 11. COMPANY PROFILES: BIOSIMILAR DEVELOPRS BASED IN ASIA-PACIFIC AND REST OF THE WORLD

11.1. Chapter Overview

11.2. Biocon

11.2.1. Company Overview

11.2.2. Financial Information

11.2.3. Biosimilar Pipeline

11.2.4. Recent Developments and Future Outlook

11.3. Dr. Reddy’s Laboratories

11.4. Celltrion

11.5. Intas Pharmaceuticals

11.6. Teva Pharmaceutical

+ 12. REGULATORY LANDSCAPE

12.1. Chapter Overview

12.2. Regulatory Guidelines for Biosimilars in North America

12.2.1. Regulatory Guidelines for Biosimilars in the US

12.2.1.1. Overview

12.2.1.2. Regulatory Landscape in the US

12.2.1.3. Regulatory Approval Pathway

12.3. Regulatory Guidelines for Biosimilars in Europe

12.3.1. Overview

12.3.2. Regulatory Landscape in Europe

12.3.3. Regulatory Approval Pathway

12.4. Regulatory Guidelines for Biosimilars in Asia-Pacific

12.4.1. Regulatory Guidelines for Biosimilars in China

12.4.1.1. Overview

12.4.1.2. Regulatory Landscape in China

12.4.1.3. Regulatory Approval Pathway

12.4.2. Regulatory Guidelines for Biosimilars in Japan

12.4.2.1. Overview

12.4.2.2. Regulatory Landscape in Japan

12.4.2.3. Regulatory Approval Pathway

12.4.3. Regulatory Guidelines for Biosimilars in Australia

12.4.3.1. Overview

12.4.3.2. Regulatory Landscape in Australia

12.4.3.3. Regulatory Approval Pathway

12.5. Future Perspectives

+ 13. COST PRICE ANALYSIS

13.1. Chapter Overview

13.2. Factors Contributing to High Price of Novel Biologics

13.3. Pricing of Biosimilars

13.3.1. Price Comparison of Different Biosimilars with its Reference Biologic

13.4. Concluding Remarks

+ 14. CASE STUDY: OUTSOURCING OF BIOSIMILARS

14.1. Chapter Overview

14.2. Need for Outsourcing Manufacturing Operations

14.3. Impact of Biosimilars on the Global Contract Manufacturing Market

14.3.1. Biosimilars: Historical Trend of FDA Approvals

14.4. Biosimilars Contract Manufacturing Service Providers

14.5. Challenges Associated with Outsourcing of Biosimilar Manufacturing Operations

14.6. Future Perspectives

+ 15. CASE STUDY: BLOCKBUSTER DRUGS LOSING PATENTS IN NEXT FIVE YEARS

15.1. Chapter Overview

15.2. Importance of Patent Expiry in the Pharmaceutical Market

15.3. Blockbuster Drugs Facing Patent Expiry (till 2030)

15.3.1. Key Drugs and their Market Impact

15.3.2. Therapeutic Areas Affected

15.4. Implications for Biosimilars and Generic Drug Market

15.5. Strategic Responses by Originator Companies

15.6. Opportunities for Biosimilar Developers and Contract Manufacturers

15.7. Future Perspectives

+ 16. DEMAND ANALYSIS

16.1. Chapter Overview

16.2. Key Assumptions and Methodology

16.2.1. Global Annual Demand for Biosimilars

16.2.1.1. Analysis by Drug Class

16.2.1.2. Analysis by Therapeutic Area

16.2.1.3. Analysis by Type of Manufacturer

16.2.1.4. Analysis by Distribution Channel

16.2.1.5. Analysis by Geographical Regions

+ 17. MARKET IMPACT ANALYSIS

17.1. Market Drivers

17.2. Market Restraints

17.3. Market Opportunities

17.4. Market Challenges

+ 18. PORTER’S FIVE FORCES ANALYSIS

18.1. Threats of New Entrants

18.2. Bargaining Power of Buyers

18.3. Bargaining Power of Suppliers

18.4. Threats of Substitute Products

18.5. Rivalry Among Existing Companies

18.6. Conclusion

+ 19. GLOBAL BIOSIMILARS MARKET

19.1. Chapter Overview

19.2. Assumptions and Methodology

19.3. Global Biosimilars Market, Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)

19.3.1. Roots Analysis Perspective on Market Growth

19.3.2. Scenario Analysis

19.3.2.1. Conservative Scenario

19.3.2.2. Optimistic Scenario

19.4. Key Market Segmentations

+ 20. BIOSIMILARS MARKET, BY DRUG CLASS

20.1. Chapter Overview

20.2. Key Assumptions and Methodology

20.3. Biosimilars Market: Distribution by Drug Class

20.3.1. Biosimilars Market for Monoclonal Antibodies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

20.3.2. Biosimilars Market for Proteins, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

20.3.3. Biosimilars Market for Peptides, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

20.3.4. Biosimilars Market for Others, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

20.4. Data Triangulation and Validation

+ 21. BIOSIMILARS MARKET, BY THERAPEUTIC AREA

21.1. Chapter Overview

21.2. Key Assumptions and Methodology

21.3. Biosimilars Market: Distribution by Therapeutic Area

21.3.1. Biosimilars Market for Oncological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

21.3.2. Biosimilars Market for Autoimmune and Inflammatory Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

21.3.3. Biosimilars Market for Hematological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

21.3.4. Biosimilars Market for Metabolic Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

21.3.5. Biosimilars Market for Other Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

21.4. Data Triangulation and Validation

+ 22. BIOSIMILARS MARKET, BY TYPE OF MANUFACTURER

22.1. Chapter Overview

22.2. Key Assumptions and Methodology

22.3. Biosimilars Market: Distribution by Type of Manufacturer

22.3.1. Biosimilars Market for Contract Manufacturers, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

22.3.2. Biosimilars Market for In-house Developers, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

22.4. Data Triangulation and Validation

+ 23. BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL

23.1. Chapter Overview

23.2. Key Assumptions and Methodology

23.3. Biosimilars Market: Distribution by Distribution Channel

23.3.1. Biosimilars Market for Hospital Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

23.3.2. Biosimilars Market for Retail Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

23.3.3. Biosimilars Market for Online Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

23.4. Data Triangulation and Validation

+ 24. BIOSIMILARS MARKET, BY GEOGRAPHICAL REGIONS

24.1. Chapter Overview

24.2. Key Assumptions and Methodology

24.3. Biosimilars Market: Distribution by Geographical Regions

24.3.1. Biosimilars Market in North America, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.1.1. Biosimilars Market in the US, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.1.2. Biosimilars Market in Canada, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.2. Biosimilars Market in Europe, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.2.1. Biosimilars Market in Germany, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.2.2. Biosimilars Market in the UK, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.2.3. Biosimilars Market in France, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.2.4. Biosimilars Market in Spain, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.2.5. Biosimilars Market in Italy, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.2.6. Biosimilars Market in Switzerland, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.2.7. Biosimilars Market in Belgium, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.2.8. Biosimilars Market in Denmark, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.2.9. Biosimilars Market in Rest of Europe, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.3. Biosimilars Market in Asia-Pacific, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.3.1. Biosimilars Market in China, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.3.2. Biosimilars Market in India, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.3.3. Biosimilars Market in Japan, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.3.4. Biosimilars Market in South Korea, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.3.5. Biosimilars Market in Australia, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.4. Biosimilars Market in Middle East and North Africa, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.4.1. Biosimilars Market in Saudi Arabia, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.4.2. Biosimilars Market in Egypt, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.4.3. Biosimilars Market in UAE, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.5. Biosimilars Market in Latin America, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.5.1. Biosimilars Market in Brazil, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.5.2. Biosimilars Market in Mexico, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.3.5.3. Biosimilars Market in Argentina, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

24.4. Market Movement Analysis

24.5. Penetration-Growth (P-G) Matrix

24.6. Data Triangulation and Validation

+ 25. BIOSIMILARS MARKET, BY LEADING PLAYERS

25.1. Chapter Overview

25.2. Key Assumptions and Methodology

25.3. Biosimilars Market: Leading Players

+ 26. BIOSIMILARS MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

26.1. Biosimilars Market in North America: Distribution by Drug Class

26.1.1. Biosimilars Market in North America for Monoclonal Antibodies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

26.1.2. Biosimilars Market in North America for Proteins, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

26.1.3. Biosimilars Market in North America for Peptides, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

26.1.4. Biosimilars Market in North America for Others, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

26.2. Biosimilars Market in North America: Distribution by Therapeutic Area

26.2.1. Biosimilars Market in North America for Oncological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

26.2.2. Biosimilars Market in North America for Autoimmune and Inflammatory Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

26.2.3. Biosimilars Market in North America for Hematological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

26.2.4. Biosimilars Market in North America for Metabolic Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

26.2.5. Biosimilars Market in North America for Other Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

26.3. Biosimilars Market in North America: Distribution by Type of Manufacturer

26.3.1. Biosimilars Market in North America for Contract Manufacturers, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

26.3.2. Biosimilars Market in North America for In-house Developers, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

26.4. Biosimilars Market in North America: Distribution by Distribution Channel

26.4.1. Biosimilars Market in North America for Hospital Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

26.4.2. Biosimilars Market in North America for Retail Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

26.4.3. Biosimilars Market in North America for Online Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

+ 27. BIOSIMILARS MARKET OPPORTUNITY ANALYSIS: EUROPE

27.1. Biosimilars Market in Europe: Distribution by Drug Class

27.1.1. Biosimilars Market in Europe for Monoclonal Antibodies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

27.1.2. Biosimilars Market in Europe for Proteins, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

27.1.3. Biosimilars Market in Europe for Peptides, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

27.1.4. Biosimilars Market in Europe for Others, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

27.2. Biosimilars Market in Europe: Distribution by Therapeutic Area

27.2.1. Biosimilars Market in Europe for Oncological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

27.2.2. Biosimilars Market in Europe for Autoimmune and Inflammatory Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

27.2.3. Biosimilars Market in Europe for Hematological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

27.2.4. Biosimilars Market in Europe for Metabolic Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

27.2.5. Biosimilars Market in Europe for Other Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

27.3. Biosimilars Market in Europe: Distribution by Type of Manufacturer

27.3.1. Biosimilars Market in Europe for Contract Manufacturers, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

27.3.2. Biosimilars Market in Europe for In-house Developers, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

27.4. Biosimilars Market in Europe: Distribution by Distribution Channel

27.4.1. Biosimilars Market in Europe for Hospital Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

27.4.2. Biosimilars Market in Europe for Retail Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

27.4.3. Biosimilars Market in Europe for Online Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

+ 28. BIOSIMILARS MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

28.1. Biosimilars Market in Asia-Pacific: Distribution by Drug Class

28.1.1. Biosimilars Market in Asia-Pacific for Monoclonal Antibodies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

28.1.2. Biosimilars Market in Asia-Pacific for Proteins, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

28.1.3. Biosimilars Market in Asia-Pacific for Peptides, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

28.1.4. Biosimilars Market in Asia-Pacific for Others, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

28.2. Biosimilars Market in Asia-Pacific: Distribution by Therapeutic Area

28.2.1. Biosimilars Market in Asia-Pacific for Oncological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

28.2.2. Biosimilars Market in Asia-Pacific for Autoimmune and Inflammatory Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

28.2.3. Biosimilars Market in Asia-Pacific for Hematological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

28.2.4. Biosimilars Market in Asia-Pacific for Metabolic Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

28.2.5. Biosimilars Market in Asia-Pacific for Other Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

28.3. Biosimilars Market in Asia-Pacific: Distribution by Type of Manufacturer

28.3.1. Biosimilars Market in Asia-Pacific for Contract Manufacturers, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

28.3.2. Biosimilars Market in Asia-Pacific for In-house Developers, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

28.4. Biosimilars Market in Asia-Pacific: Distribution by Distribution Channel

28.4.1. Biosimilars Market in Asia-Pacific for Hospital Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

28.4.2. Biosimilars Market in Asia-Pacific for Retail Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

28.4.3. Biosimilars Market in Asia-Pacific for Online Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

+ 29. BIOSIMILARS MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

29.1. Biosimilars Market in Middle East and North Africa: Distribution by Drug Class

29.1.1. Biosimilars Market in Middle East and North Africa for Monoclonal Antibodies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

29.1.2. Biosimilars Market in Middle East and North Africa for Proteins, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

29.1.3. Biosimilars Market in Middle East and North Africa for Peptides, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

29.1.4. Biosimilars Market in Middle East and North Africa for Others, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

29.2. Biosimilars Market in Middle East and North Africa: Distribution by Therapeutic Area

29.2.1. Biosimilars Market in Middle East and North Africa for Oncological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

29.2.2. Biosimilars Market in Middle East and North Africa for Autoimmune and Inflammatory Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

29.2.3. Biosimilars Market in Middle East and North Africa for Hematological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

29.2.4. Biosimilars Market in Middle East and North Africa for Metabolic Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

29.2.5. Biosimilars Market in Middle East and North Africa for Other Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

29.3. Biosimilars Market in Middle East and North Africa: Distribution by Type of Manufacturer

29.3.1. Biosimilars Market in Middle East and North Africa for Contract Manufacturers, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

29.3.2. Biosimilars Market in Middle East and North Africa for In-house Developers, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

29.4. Biosimilars Market in Middle East and North Africa: Distribution by Distribution Channel

29.4.1. Biosimilars Market in Middle East and North Africa for Hospital Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

29.4.2. Biosimilars Market in Middle East and North Africa for Retail Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

29.4.3. Biosimilars Market in Middle East and North Africa for Online Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

+ 30. BIOSIMILARS MARKET OPPORTUNITY ANALYSIS: LATIN AMERICA

30.1. Biosimilars Market in Latin America: Distribution by Drug Class

30.1.1. Biosimilars Market in Latin America for Monoclonal Antibodies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

30.1.2. Biosimilars Market in Latin America for Proteins, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

30.1.3. Biosimilars Market in Latin America for Peptides, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

30.1.4. Biosimilars Market in Latin America for Others, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

30.2. Biosimilars Market in Latin America: Distribution by Therapeutic Area

30.2.1. Biosimilars Market in Latin America for Oncological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

30.2.2. Biosimilars Market in Latin America for Autoimmune and Inflammatory Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

30.2.3. Biosimilars Market in Latin America for Hematological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

30.2.4. Biosimilars Market in Latin America for Metabolic Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

30.2.5. Biosimilars Market in Latin America for Other Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

30.3. Biosimilars Market in Latin America: Distribution by Type of Manufacturer

30.3.1. Biosimilars Market in Latin America for Contract Manufacturers, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

30.3.2. Biosimilars Market in Latin America for In-house Developers, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

30.4. Biosimilars Market in Latin America: Distribution by Distribution Channel

30.4.1. Biosimilars Market in Latin America for Hospital Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

30.4.2. Biosimilars Market in Latin America for Retail Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

30.4.3. Biosimilars Market in Latin America for Online Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

**Detailed information on Chapter 26 to30 is available in the Excel Data Packs shared along with the report**

+ 31. CONCLUDING REMARKS

+ 32. EXECUTIVE INSIGHTS

+ 33. APPENDIX I: TABULATED DATA

+ 34. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

+ List of Figures

Figure 2.1 Research Methodology: Project Methodology

Figure 2.2 Research Methodology: Data Sources for Secondary Research

Figure 2.3 Research Methodology: Robust Quality Control

Figure 3.1 Market Dynamics: Forecast Methodology

Figure 3.2 Market Dynamics: Market Assessment Framework

Figure 4.1 Lessons Learnt from Past Recessions

Figure 5.1 Executive Summary: Market Landscape

Figure 5.2 Executive Summary: Market Trends

Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis

Figure 6.1 Number of Biologics Approved by the USFDA, Since 2015

Figure 6.2 Need for Biosimilars

Figure 6.3 Steps Involved in Upstream Processing

Figure 6.4 Steps Involved in Downstream Processing

Figure 6.5 Reference Biologic and Biosimilar Development Timeline

Figure 7.1 Biosimilar Developers: Distribution by Year of Establishment

Figure 7.2 Biosimilar Developers: Distribution by Company Size

Figure 7.3 Biosimilar Developers: Distribution by Location of Headquarters (Region)

Figure 7.4 Biosimilar Developers: Distribution by Location of Headquarters (Country)

Figure 7.5 Biosimilars: Distribution by Stage of Development

Figure 7.6 Biosimilars: Distribution by Therapeutic Area

Figure 7.7 Biosimilars: Distribution by Drug Class

Figure 8.1 Company Competitiveness Analysis: Biosimilar Developers based in North America

Figure 8.2 Company Competitiveness Analysis: Biosimilar Developers based in Europe

Figure 8.3 Company Competitiveness Analysis: Biosimilar Developers based in Asia-Pacific and Rest of the World

Figure 9.1 Amgen: Consolidated Financial Details (USD Billon)

Figure 9.2 Coherus BioSciences: Consolidated Financial Details (USD Millon)

Figure 9.3 Eli Lilly: Consolidated Financial Details (USD Billion)

Figure 9.4 Pfizer: Business Segment-wise Revenues and Consolidated Financial Details (USD Million)

Figure 10.1 Fresenius Kabi: Business Segment-wise Revenues and Consolidated Financial Details (EUR Million)

Figure 10.2 Sandoz: Consolidated Financial Details (USD Million)

Figure 10.3 STADA: Business Segment-wise Revenues and Consolidated Financial Details (EUR Million)

Figure 11.1 Biocon: Business Segment-wise Revenues and Consolidated Financial Details (INR Billon)

Figure 11.2 Dr. Reddy’s Laboratories: Business Segment-wise Revenues and Consolidated Financial Details (INR Billion)

Figure 11.3 Celltrion: Consolidated Financial Details (KRW Billion)

Figure 11.4 Teva Pharmaceutical: Consolidated Financial Details (USD Billion)

Figure 12.1 Regulatory Approval Pathways for Biologics and Biosimilars in the US

Figure 12.2 Comparability Study Steps for Biosimilar Development in Europe

Figure 12.3 Guidelines and Approval Pathway for Biosimilar Development in China

Figure 12.4 Guidelines for Approval of Biosimilars in Australia

Figure 13.1 Potential Cost Saving Projections

Figure 14.1 Need for Outsourcing Biosimilar Manufacturing Operations

Figure 14.2 Biosimilars: Historical Trend of FDA Approvals, Since 2015

Figure 14.3 Challenges Associated with Outsourcing Biosimilar Manufacturing Operations

Figure 15.1 Blockbuster Drugs Facing Patent Expiry (till 2030)

Figure 16.1 Global Annual Demand for Biosimilars, Since 2019 (in units)

Figure 16.2 Global Demand for Biosimilars: Distribution by Drug Class (in units)

Figure 16.3 Global Demand for Biosimilars: Distribution by Therapeutic Area (in units)

Figure 16.4 Global Demand for Biosimilars: Distribution by Type of Manufacturer (in units)

Figure 16.5 Global Demand for Biosimilars: Distribution by Distribution Channel (in units)

Figure 16.6 Global Demand for Biosimilars: Distribution by Geographical Regions (in units)

Figure 18.1 Porter’s Five Forces: Key Parameters

Figure 18.2 Porter’s Five Forces: Harvey Ball Analysis

Figure 19.1 Global Biosimilars Market, Historical Trends (since 2019) and Forecasted Estimates (Till 2035) (USD Million)

Figure 19.2 Global Biosimilars Market, Forecasted Estimates (Till 2035) (USD Million): Conservative Scenario

Figure 19.3 Global Biosimilars Market, Forecasted Estimates (Till 2035) (USD Million): Optimistic Scenario

Figure 20.1 Biosimilars Market: Distribution by Drug Class

Figure 20.2 Biosimilars Market for Monoclonal Antibodies, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Million)

Figure 20.3 Biosimilars Market for Proteins, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Million)

Figure 20.4 Biosimilars Market for Peptides, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Million)

Figure 20.5 Biosimilars Market for Others, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Million)

Figure 21.1 Biosimilars Market: Distribution by Therapeutic Area

Figure 21.2 Biosimilars Market for Oncological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Million)

Figure 21.3 Biosimilars Market for Autoimmune and Inflammatory Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Million)

Figure 21.4 Biosimilars Market for Hematological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Million)

Figure 21.5 Biosimilars Market for Metabolic Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Million)

Figure 21.6 Biosimilars Market for Other Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Million)

Figure 22.1 Biosimilars Market: Distribution by Type of Manufacturer

Figure 22.2 Biosimilars Market for Contract Manufacturers, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Million)

Figure 22.3 Biosimilars Market for In-house Developers, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Million)

Figure 23.1 Biosimilars Market: Distribution by Distribution Channel

Figure 23.2 Biosimilars Market for Hospital Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Million)

Figure 23.3 Biosimilars Market for Retail Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Million)

Figure 23.4 Biosimilars Market for Online Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Million)

Figure 24.1 Biosimilars Market: Distribution by Geographical Regions

Figure 24.2 Biosimilars Market in North America, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.3 Biosimilars Market in the US, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.4 Biosimilars Market in Canada, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.5 Biosimilars Market in Europe, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.6 Biosimilars Market in Germany, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.7 Biosimilars Market in the UK, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.8 Biosimilars Market in France, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.9 Biosimilars Market in Spain, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.10 Biosimilars Market in Italy, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.11 Biosimilars Market in Switzerland, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.12 Biosimilars Market in Belgium, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.13 Biosimilars Market in Denmark, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.14 Biosimilars Market in Rest of Europe, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.15 Biosimilars Market in Asia-Pacific, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.16 Biosimilars Market in China, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.17 Biosimilars Market in India, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.18 Biosimilars Market in Japan, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.19 Biosimilars Market in South Korea, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.20 Biosimilars Market in Australia, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.21 Biosimilars Market in Middle East and North Africa, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.22 Biosimilars Market in Saudi Arabia, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.23 Biosimilars Market in Egypt, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.24 Biosimilars Market in UAE, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.25 Biosimilars Market in Latin America, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.26 Biosimilars Market in Brazil, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.27 Biosimilars Market in Mexico, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.28 Biosimilars Market in Argentina, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

Figure 24.29 Biosimilars Market: Market Movement Analysis

Figure 24.30 Biosimilars Market: Penetration-Growth (P-G) Matrix

Figure 25.1 Biosimilars Market: Leading Players

Figure 31.1 Concluding Remarks: Market Landscape

Figure 31.2 Concluding Remarks: Demand Analysis

Figure 31.3 Concluding Remarks: Market Forecast and Opportunity Analysis

+ List of Tables

Table 6.1 Difference between Reference Biologics, Biosimilars and Generics

Table 13.1 Price Comparison of Different Biosimilars with their Reference Biologics

Table 14.1 List of Biosimilars Contract Manufacturing Service Providers

Table 25.1 Leading Industry Players: Based on the Company Size and Number of Approved Biosimilars

Table 33.1 Biosimilar Developers: Distribution by Year of Establishment

Table 33.2 Biosimilar Developers: Distribution by Company Size

Table 33.3 Biosimilar Developers: Distribution by Location of Headquarters (Region)

Table 33.4 Biosimilar Developers: Distribution by Location of Headquarters (Country)

Table 33.5 Biosimilars: Distribution by Stage of Development

Table 33.6 Biosimilars: Distribution by Therapeutic Area

Table 33.7 Biosimilars: Distribution by Drug Class

Table 33.8 Amgen: Consolidated Financial Details (USD Billion)

Table 33.9 Coherus BioSciences: Consolidated Financial Details (USD Million)

Table 33.10 Eli Lilly: Consolidated Financial Details (USD Billion)

Table 33.11 Pfizer: Business Segment-wise Revenues and Consolidated Financial Details (USD Million)

Table 33.12 Fresenius Kabi: Business Segment-wise Revenues and Consolidated Financial Details (EUR Million)

Table 33.13 Sandoz: Consolidated Financial Details (USD Million)

Table 33.14 STADA: Business Segment-wise Revenues and Consolidated Financial Details (EUR Million)

Table 33.15 Biocon: Business Segment-wise Revenues and Consolidated Financial Details (INR Billion)

Table 33.16 Dr. Reddy’s Laboratories: Business Segment-wise Revenues and Consolidated Financial Details (INR Billion)

Table 33.17 Celltrion: Consolidated Financial Details (KRW Billion)

Table 33.18 Teva Pharmaceutical: Consolidated Financial Details (USD Billion)

Table 33.19 Global Annual Demand for Biosimilars, Since 2019 (in units)

Table 33.20 Global Demand for Biosimilars: Distribution by Drug Class (in units)

Table 33.21 Global Demand for Biosimilars: Distribution by Therapeutic Area (in units)

Table 33.22 Global Demand for Biosimilars: Distribution by Type of Manufacturer (in units)

Table 33.23 Global Demand for Biosimilars: Distribution by Distribution Channel (in units)

Table 33.24 Global Demand for Biosimilars: Distribution by Geographical Regions (in units)

Table 33.25 Global Biosimilars Market, Historical Trends (since 2019) and Forecasted Estimates (till 2035) (USD Million)

Table 33.26 Global Biosimilars Market, Forecasted Estimates (till 2035) (USD Million): Conservative Scenario

Table 33.27 Global Biosimilars Market, Forecasted Estimates (till 2035) (USD Million): Optimistic Scenario

Table 33.28 Biosimilars Market: Distribution by Drug Class

Table 33.29 Biosimilars Market for Monoclonal Antibodies, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.30 Biosimilars Market for Proteins, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.31 Biosimilars Market for Peptides, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.32 Biosimilars Market for Others, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.33 Biosimilars Market: Distribution by Therapeutic Area

Table 33.34 Biosimilars Market for Oncological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.35 Biosimilars Market for Autoimmune and Inflammatory Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.36 Biosimilars Market for Hematological Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.37 Biosimilars Market for Metabolic Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.38 Biosimilars Market for Other Disorders, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.39 Biosimilars Market: Distribution by Type of Manufacturer

Table 33.40 Biosimilars Market for Contract Manufacturers, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.41 Biosimilars Market for In-house Developers, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.42 Biosimilars Market: Distribution by Distribution Channel

Table 33.43 Biosimilars Market for Hospital Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.44 Biosimilars Market for Retail Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.45 Biosimilars Market for Online Pharmacies, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.46 Biosimilars Market: Distribution by Geographical Regions

Table 33.47 Biosimilars Market in North America, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.48 Biosimilars Market in the US, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.49 Biosimilars Market in Canada, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.50 Biosimilars Market in Europe, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.51 Biosimilars Market in Germany, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.52 Biosimilars Market in the UK, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.53 Biosimilars Market in France, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.54 Biosimilars Market in Spain, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.55 Biosimilars Market in Italy, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.56 Biosimilars Market in Switzerland, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.57 Biosimilars Market in Belgium, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.58 Biosimilars Market in Denmark, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.59 Biosimilars Market in Rest of Europe, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.60 Biosimilars Market in Asia-Pacific, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.61 Biosimilars Market in China, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.62 Biosimilars Market in India, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.63 Biosimilars Market in Japan, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.64 Biosimilars Market in South Korea, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.65 Biosimilars Market in Australia, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.66 Biosimilars Market in Middle East and North Africa, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.67 Biosimilars Market in Saudi Arabia, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.68 Biosimilars Market in Egypt, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.69 Biosimilars Market in UAE, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.70 Biosimilars Market in Latin America, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.71 Biosimilars Market in Brazil, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.72 Biosimilars Market in Mexico, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

Table 33.73 Biosimilars Market in Argentina, Historical Trends (since 2019) and Forecasted Estimates (till 2035): Conservative, Base and Optimistic Scenarios (USD Million)

+ List of Companies and Organizations

Please reach out to our team for more details.

Biosimilars Market 2nd Edition, 2026 to 2035